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Background: Lithium, used for treating bipolar disease, crosses freely the placenta and is classiﬁed as teratogenic.
It is unclear to what extent environmental lithium exposure may affect fetal growth and development.
Objectives: To elucidate potential effects of lithium exposure through drinking water during pregnancy on fetal
size.
Methods:We developed a prospective population-based mother–child cohort (N = 194) in an area with highly
varying drinking water lithium concentrations (5-1600 μg/L) in northern Argentinean Andes. Blood and urinary
lithium concentrations (sampled repeatedly during pregnancy) were measured using inductively coupled plas-
mamass spectrometry. Wemeasured fetal size by ultrasound in second and third trimesters, and weight, length
and head circumference at birth.Multivariablemodelswere used to examine associations between lithiumexpo-
sure (continuous and in tertiles) and fetal size measures.
Results: Lithium in maternal blood (median 25; range 1.9–145 μg/L) and urine (1645; 105–4600 μg/L) was in-
versely associated (apparently linearly) with all fetal measures (body, head and femur) in the second trimester,
and with birth length (β−0.53 cm per 25 μg/L increase in blood lithium, 95%CI−1.0;−0.052). An increase of
100 μg/L in blood was associated with 2 cm shorter newborns (about one standard deviation).
Conclusions: Lithiumexposure through drinkingwaterwas associatedwith impaired fetal size and this seemed to
be initiated in early gestation. Further studies are warranted to conﬁrm causality and to understand the mecha-
nisms. If conﬁrmed, theseﬁndings have public health relevance and emphasize the need formore data on lithium
concentrations in drinking water, including bottled water.© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lithium has long been used in the treatment of bipolar disease
(Grandjean and Aubry, 2009b). It is classiﬁed as teratogenic (category
D) by the U.S. Food and Drug Administration. Besides fetal cardiac and
other malformations, lithium seems to increase the risk of miscarriages
and prematurity, as well as fetal goiter and hypothyroidism (Cohenductively coupled plasmamass
nic; MMA, methylarsonic acid;
d chromatography; HG, hydride
r;OFD,occipitofrontaldiameter;
, femur length; BMI, bodymass
declare that they have no com-
. This is an open access article underet al., 1994; Diav-Citrin et al., 2014; Gentile, 2012; Grandjean and
Aubry, 2009c; Oyebode et al., 2012).
A source of more general exposure to lithium is drinking water,
although data on concentrations are scarce. Lithium concentrations be-
tween b1 and 170 μg/L have been reported for drinking water in Texas,
Japan and England (Bluml et al., 2013; Kabacs et al., 2011; Sugawara
et al., 2013), while concentrations exceeding 1000 μg/L have been re-
ported for certain areas in Austria (Kapusta et al., 2011) and northern
Chile (Zaldivar, 1980). High concentrations have also been reported
for certain bottled water, e.g. with almost 10 mg/L in a product from
Slovakia (Reimann and Birke, 2010). Elevated lithium concentrations
in drinkingwater (~1000 μg/L) and human urine (~4500 μg/L)were de-
tected in the Andean part of northern Argentina (Concha et al., 2010).
We recently reported that lithium from drinking water easily passes
the placenta to the fetus (Harari et al., 2012). As it is unclear to what
extent lithium, even from medication, may affect fetal growth and de-
velopment (Diav-Citrin et al., 2014; Jacobson et al., 1992; Kallen and
Tandberg, 1983; Mroczka et al., 1983), we initiated a population-the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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effects from maternal exposure to drinking water lithium during
pregnancy.
2. Material and methods
2.1. Study population
All pregnant women living in the Andean part of the Salta province
(Departamento Los Andes and part of Departamento La Poma and
Rosario de Lerma), northern Argentina (altitude 3180–4070 m above
sea level), with estimated delivery date between October 2012 and
December 2013, were invited to participate in this longitudinal
mother–child cohort, designed to evaluate potential health effects
of early-life exposure to lithium and other water pollutants. The
study area (totally 8135 inhabitants) included the main village San
Antonio de los Cobres (5893 inhabitants; mean water lithium
640 μg/L) and the surrounding villages Santa Rosa de los Pastos
Grandes (110 μg/L), Tolar Grande (8 μg/L), Salar de Pocitos
(100 μg/L), Olacapato (23 μg/L), Cobres (135 μg/L), Las Cuevas
(98 μg/L), El Toro (65 μg/L), El Palomar (13 μg/L) and Esquina de
Guardia (140 μg/L). The presence of elevated concentrations of arse-
nic in the drinking water, particularly in San Antonio de los Cobres,
has been known since long (Vahter et al., 1995), while the presence
of lithium, boron and cesium was recently detected (Concha et al.,
2010).
All pregnantwomenwere invited to the studywith the assistance of
the primary health care personnel at the hospital in San Antonio de los
Cobres and surrounding villages. The 23 trained community health care
workers visit the 20 different administrative areas (San Antonio de los
Cobres comprising 11 areas, and 9 surrounding villages) on a regular
basis, about every 3 months to update demographic information,
including health status and pregnancies. Between October 2012 and
December 2013, 221 women were pregnant, out of whom 194 became
enrolled (participation rate: 88%). Reasons for not participating includ-
ed deliveries before recruitment (n=11), twin pregnancy (n=1), fetal
loss before recruitment (n= 5), refusal or not located (n= 6), and mi-
gration (n = 4). In addition, two women had spontaneous abortions
and 12 lacked prenatal exposure data, giving a ﬁnal sample of 180 preg-
nantwomen (see Supplementarymaterial, Fig. S1).We formally invited
thewomen to themain hospital in SanAntonio de los Cobres or the local
primary health care clinics in surrounding villages for the investigation
of exposures and pregnancy-related conditions. In case a woman was
not able to attend at the scheduled date, she was asked to come any
day before or after. In this manner, all women were given maximum
opportunity to participate in the examinations. The study was designed
to see the pregnant women at least once during pregnancy; preferably
2–3 times in order to obtain repeated measures of exposure and fetal
size.
The study was approved by the regional ethical committee at
Karolinska Institutet, Stockholm, Sweden, and by theMinistry of Health,
Salta, Argentina. Prior to recruitment we obtained written informed
consent from all women after oral and written explanation of study
details. For women below 18 years of age, informed consent was also
obtained from the closest caregiver. We regularly reported to and
discussed measured water contaminant concentrations with the hospi-
tal and the Health Ministry in Salta.
2.2. Data and sample collection
All women were interviewed about age, last menstrual period
(LMP), pre-pregnancy weight, parity, time and place of residence, tap
water sources and type of water (tap/bottled water), dietary habits,
family income, living conditions, smoking, passive smoking, alcohol
consumption, coca chewing and personal and familial history of dis-
eases. We measured the women's weight (HCG-210QM, GA.MA®professional, Italy; accurate to 100 g) and height in a standardized
way at each visit. Hemoglobin levels were measured in whole blood
by HemoCue® 201+ (HemoCue AB, Ängelholm, Sweden). Gestational
agewas calculated based on the date of LMPwhichwas checked against
the estimation based on ultrasound. If LMP was not available or clearly
wrong, we used the data based on ultrasound.
All women were asked to donate blood and spot-urine samples at
baseline and at each follow-up visit. Whole blood samples were collect-
ed in Trace Elements Sodium Heparin tubes (Vacuette®; Greiner bio-
one, Kremsmünster, Austria) with butterﬂy needles (BD Safety-Lok™,
Vacutainer®, Becton, Dickinson and Company, Franklin Lakes, USA;
tested negative for trace element contamination). One tube was centri-
fuged for 10 min at 3000 rpm, 15 min after blood withdrawal, for plas-
ma extraction. Spot-urine samples were collected at the hospital or at
the local health clinics using disposable trace element free plastic cups
and transferred to 20 mL polyethylene bottles. Instructions on wet
wipe cleaning and appropriate mid-stream urine sample collection
were given in order to avoid contamination. We repeatedly collected
water samples (20 mL polyethylene bottles). Blood, urine and water
samples were kept at−20 °C until transported to Karolinska Institutet,
Sweden, where they were stored at−80 °C until analysis.
2.3. Exposure assessment
To assess lithium exposure, we measured the concentrations in
blood, urine, and drinking water. We also measured arsenic, boron
and cesium in the same media to control for potential confounding, as
they are also present in the drinking water in the study area. All ele-
ments were determined using inductively coupled plasma mass spec-
trometry (ICP-MS, Agilent 7700× ORS ICP-MS, Agilent Technologies,
Tokyo, Japan), with the collision/reaction cell in no gas mode (lithium,
boron and cesium) or helium mode (arsenic). Before analysis, urine
and water samples were diluted 1:10 with 1% nitric acid (65% w/w,
ppb-trace analysis grade, Scharlau, Scharlab S.L., Sentmenat, Spain)
(Concha et al., 2010). Aliquots (0.2 mL) of blood samples were diluted
1:25 with an alkali solution consisting of 1-butanol 2% (w/v), EDTA
0.05% (w/v), triton X-100 0.05% (w/v), NH4OH 1% (w/v) and internal
standards (20 μg/L) (Lu et al., 2015). The mixture was sonicated for
5 min and centrifuged at 2000 rpm for 5 min (MSE centrifuge, Super
Minor, MSE (UK) Ltd., London, England) before ICP-MS analysis. This
method was found to provide more reliable results for blood lithium
than acid digestion (Lu et al., 2014). For urine, acid and alkaline dilution
gave essentially the same results (rs = 0.98; n= 285). Results for com-
mercially available reference materials and limits of detection are pre-
sented in Supplemental material, Table S1.
Concentrations of inorganic arsenic (iAs) and its methylated metab-
olites methylarsonic acid (MMA) and dimethylarsinic acid (DMA) in
urinewere determined using high-performance liquid chromatography
(HPLC) coupledwith hydride generation (HG) and ICP-MS as previously
described (Harari et al., 2013). The sum of the metabolite concentra-
tions in urine (iAs + MMA+ DMA) was used as exposure marker for
inorganic arsenic. For quality control, see Harari et al. (2013). The corre-
lation between concentrations of sum of arsenic metabolites and total
arsenic, measured in multi-element analyses, was 0.97 (p b 0.001),
supporting reliable analytical data, and also that thewomenwere exclu-
sively exposed to inorganic arsenic (Vahter, 2002).
To compensate for variations in the dilution of urine, the measured
element concentrations were adjusted to the mean urinary osmolality
(694 mOsm/kg; range 141–1174), measured by a digital cryoscopic
osmometer (OSMOMAT® 030, Gonotec Gesellschaft für Meß- und
Regeltechnik mbH, Berlin, Germany). Osmolality was chosen since cre-
atinine adjustment is markedly affected by muscle mass, age and meat
intake (Suwazono et al., 2005) and speciﬁc gravity by urinary protein
and glucose (Parikh et al., 2002). Microalbuminuria (urinary albumin
30–299mg/L)was detected in 14% of all women andmacroalbuminuria
(N300 mg/L) in 6%, using HemoCue Albumin 201 (HemoCue AB,
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2.4. Fetal growth parameters
Of the 180 included women, 136 participated in at least one ultra-
soundmeasurement (October 2012, January 2013 and April 2013) dur-
ing the 2nd (n = 81) or 3rd (n = 98) trimester (43 of them had
measurements in both 2nd and 3rd trimesters) and ten women were
measured only in the 1st trimester (34 women had no measurement).
The examinations were performed by an experienced senior obstetri-
cian, using a portable ultrasound machine FFSonic, UF-4100, (Fukuda
Denshi, Tokyo, Japan) with 3.5 MHz transducer (FUT-CS602-5AJ). The
measurements included biparietal diameter (BPD), occipitofrontal di-
ameter (OFD), head circumference (HC), abdominal circumference
(AC), and femur length (FL). BPD, OFD, and HC were all calculated from
a plane of the head where the thalamus, the cavum septum pellucidum
and the choroid plexus were included. BPD was measured from the
outer to inner skull bone, OFD from the outer to inner skull bone and
HC around the outer table of the skull. ACwas calculated from a cross sec-
tion of the abdomen, circular in shape, and in right angle to the spinewith
the stomach, the umbilical vein and a cross section of the spine were in-
cluded. AC was measured around the outer table of this abdominal pic-
ture. FL was measured as the whole diaphysis of the femur. Each site
was measured three times, each time using a new picture, after which
the averagewas calculated. Fetalweightwas calculated by the instrument
software according to the following formula: Log10Fetal Weight (g) =
(AC ∗ 0.046)− (BPD ∗AC ∗ 0.002646)+ (BPD ∗ 0.166)+1.2508. Indicat-
ed abnormalities (heart malformation (n = 1), renal cysts (n = 1),
polyhydramnios (n=1) oligoamnios (n=1))were referred by themed-
ical doctors to the main obstetric clinic in Salta.
2.5. Measurements at birth
Birth anthropometric measures were obtained within a few hours
after birth for 174 of the women (see Supplemental material, Fig. S1).
Of these, seven women (4.0%) had delivered at home and six women
(3.5%), in the ambulance on the way to Salta hospital. Birth weight
was measured using a baby balance (Seca 725 Mechanical Beam Baby
Scale, Brooklyn, NY, USA), birth length using a portable wood
infantometer to the nearest 5 mm with the child in supine position,
and head circumference with a soft, non-stretchable plastic tape line.
Gestational age at birth was calculated by subtracting the date for LMP
from the date of birth. In the few cases of missing LMP, we used the
ultrasound estimation.
2.6. Statistical methods
Statistical analyses were performed with STATA 12.1 (StataCorp LP,
TX, USA). A p-value of b0.05 was considered statistically signiﬁcant.
Initial bivariate associations between exposure markers, fetal growth
parameters and outcomes, and potential covariates were assessed
with Spearman's rank correlation (rs).We also visually evaluated scatter
plots of all the outcomes against exposure measures and covariates and
examined the associations with Lowess moving-average ﬁtted curves.
For the test of differences across tertiles of blood lithium,Kruskal–Wallis
rank test (for continuous variables) and chi-square test (for categorical
variables) were used.
To elucidate associations of maternal lithium exposure with fetal
growth, we performed multivariable-adjusted linear regression analy-
ses, including measurements in the 2nd and 3rd trimesters (only
crown-rump length was measured in the ﬁrst trimester), using blood
and urine lithium as continuous variables as well as in tertiles. Because
the fetal and exposure measurements were collected prospectively, we
modeled the mean changes in these parameters over time using linear
mixed effect models with random intercept and slope using maximumlikelihood estimation. As blood and urine lithium seemed to change
across pregnancy, based on linear mixed-effects models including all
measurements obtained throughout pregnancy (N = 282), we also
performed cross-sectional linear regression analyses with fetal size
measurements in the second and third trimesters separately. For the
birth outcomeswe used linear regressionmodels based on the apparent
linear associations when visually examining the Lowess moving-
averageﬁtted curves for birthmeasurements against lithium concentra-
tions during pregnancy (mean value for women with two or more
measurements).
Initially, each fetal/birth measurement was regressed against blood
or urinary lithium (measured at the same time as the outcome for
fetal measurements, or average of blood and urine measurements dur-
ing pregnancy for birth measurements) adjusting only for gestational
age at measurement (in weeks) and gestational age as quadratic term,
as the associations between fetal measurements and gestational age ap-
peared to be quadratic. For comparison, we tested adjusting themodels
for centered gestational age and obtained the same results. Further ad-
justment was based on a priori selection of known risk factors for low
fetal or birth size and on results from exploratory stepwise regression
using an approach of bidirectional elimination of covariates, i.e. a com-
bination of forward selection and backward elimination. Allﬁnalmodels
were adjusted for parity, family monthly income (from both mother
and father in tertiles:≤500, 500–3000, N3000 Argentine pesos), mater-
nal height (cm), fetal sex, maternal urinary arsenic (continuous), blood
cesium (continuous) and serum boron (b or≥80 μg/L). Family monthly
incomewas used as an index of socioeconomic status as this inﬂuenced
the models more than maternal or paternal education level and living
conditions. Other covariates such as coca chewing, hemoglobin concen-
trations, history of diseases, blood pressure and pre-pregnancy weight
did not inﬂuence the estimates and were, therefore, not included in
the ﬁnal adjusted models. Because of collinearity between maternal
age and parity (rs = 0.79, p b 0.001), we only included parity in the
models as that explained more than maternal age.
To test whether the right-skewed exposure data inﬂuenced the
obtained estimates, we repeated the analyses using blood or urinary
lithium categorized in tertiles, adjusting the models for the same vari-
ables as in the previous analyses. In sensitivity analyses, we excluded
one individual with the highest blood lithium level (145 μg/L) and
two women with preeclampsia from all models.
3. Results
Cohort characteristics and birth outcomes are presented in Table 1
by tertiles of blood lithium, and measurements of fetal BPD, OFD, HC,
AC, and FL and calculated weight of the 136 fetuses (total number of
measurements = 179) in fetal growth charts (see Supplemental mate-
rial, Fig. S2). Thirteen percent of thewomenwere younger than 18 years
and 19% older than 30. Half of the women were shorter than 153 cm, in
agreement with other Andean populations (Macdonald et al., 2004),
which tended to give high body mass index (BMI). In total 12% of the
women had a BMI of 25–30 kg/m2 and 7% above 30. Thirty-ﬁve percent
of the women were nullipara (age range 13–29 years) and the
maximum number of previous births was 12. Eighteen percent of the
women delivered preterm. The women were mostly of indigenous ori-
gin; with 85% reportedly belonging to the Kolla community (85%) and
some to the Atacama and Tastil communities. Two thirds of the families
owned their houses,which often (92%)were built of adobe,withﬂoor of
mud (40%) or cement (55%) and roof of tin and/or stones (51%) or straw
and wood (43%). Only 13% lived in rented room or small apartment.
Median lithium concentration in maternal blood and urine among
all 180 women (irrespective of number of samples per woman) was
25 (range 1.9–145) μg/L and 1491 (105–4598) μg/L, respectively. The
exposure to all the metals lithium, arsenic, boron, and cesium increased
signiﬁcantly across tertiles of blood lithium (Table 1), however, they
were, in general, weakly or moderately correlated (Supplemental
Table 1
Household and maternal characteristics and birth outcomes by tertiles of maternal lithium concentrations in blooda (μg/L).
Mean (range): Tertile 1 (n = 60) Tertile 2 (n = 60) Tertile 3 (n = 59)
11 (1.9–18.4) 25 (18.7–31.3) 47 (31.3–145) p-Valueb
Household charactertistics
Household (number of people) 6.4 (3.5) 2.0–17 7.4 (4.5) 1.0–24 7.4 (4.4) 2.0–32 0.22
Water lithium (μg/L) 126 8.2–819 670 27–819 750 6.5–958 b0.001
Water arsenic (μg/L) 52 1.7–157 97 3.4–157 100 4.4–157 b0.001
Water boron (μg/L) 3142 377–6655 5565 846–6525 6072 402–10,930 b0.001
Water cesium (μg/L) 154 0.0061–356 299 0.15–366 325 0.058–392 b0.001
Maternal charactertistics
Maternal age (years) 25 (6.9) 15–41 24 (6.3) 14–37 25 (7.2) 13–40 0.76
Height (cm) 154 (5.6) 144–169 153 (5.5) 144–168 151 (4.8) 134–161 0.11
Pre-pregnancy weight (kg)c 56 (10) 40–86 54 (8.3) 42–74 52 (8.3) 38–77 0.12
Pre-pregnancy BMI (Kg/m2) 23 (3.4) 18–35 23 (3.6) 18–32 23 (3.9) 17–35 0.65
Maternal education level (years) 8.9 (3.3) 0.0–16 8.9 (3.7) 0.0–17 9.2 (3.5) 0.0–15 0.16
Residence time (years) 17 (9.8) 0.25–40 19 (9.5) 0.17–37 20 (10) 0.13–40 0.24
Parity (n) 1.9 (2.7) 0.0–11 2.0 (2.4) 0.0–12 1.9 (2.4) 0.0–8.0 0.84
Nullipara (%) 38% 37% 37% 0.99
History of Preeclampsy (%) 5% 10% 5% 0.44
Coca users (%) 43% 40% 49% 0.64
Urinary lithium (μg/L)a,d 745 105–1660 1478 920–4183 2516 1078–4598 b0.001
Urinary arsenic (μg/L)a,d 59 13–943 149 25–556 218 57–2450 b0.001
Whole blood cesium (μg/L)a 66 2.5–470 117 6.2–685 147 11–362 b0.001
Serum boron (μg/L)a 78 0.13–212 127 59–245 198 112–605 b0.001
Birth outcomes
Gestational age at birth (weeks) 39 (2.7) 29–42 39 (2.1) 32–42 38 (2.5) 30–42 0.48
Preterm (gestational week b37, %) 22% 15% 17% 0.63
Low birth weight (b2500 g, %) 5% 12% 7% 0.44
Weight (g) 3035 (489) 1250–4500 3043 (454) 1760–4130 3002 (461) 1260–4165 0.76
Length (cm) 48 (2.5) 40–51 48 (2.1) 42–53 47 (2.5) 39–51 0.24
Head circunference (cm) 34 (1.9) 26–37 34 (1.7) 30–40 34 (1.6) 29–36 0.44
Values presented as mean (SD), median or percent (%), and range (minimum–maximum).
Abbreviations: BMI: body mass index.
a Based on the mean concentration during pregnancy.
b Based on Kruskal–Wallis rank test for continuous variables and Chi square test for categorical variables.
c Based on post-pregnancy weight (3–6 months post-partum) in 13.5% of individuals.
d Urinary concentrations are adjusted for the mean urinary osmolality from all women (694 mOsm/Kg).
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and urinary lithiumwas 0.84 (p b 0.001), that for blood andwater lithium
0.40 (p b 0.001) and that for urine and water lithium 0.44 (p b 0.001).
Blood lithium increased during pregnancy, particularly in the last trimes-
ter, while urine lithium increased more constantly across gestation (32%
over 30 weeks; see Supplemental material, Fig. S3A and B). None of the
women reported being diagnosed with mental diseases or under lithium
treatment.3.1. Associations between lithium exposure and fetal size
The initial linear mixed-effect regression analyses showed no associa-
tions between blood lithium and the different fetal measurements,
neither using the basic adjustment (gestational age (inweeks and as qua-
dratic term)), norwith the further adjustment (parity, familymonthly in-
come, maternal height, fetal sex, maternal urinary arsenic, blood cesium
and serumboron) (see Supplementalmaterial, Table S3). Associations be-
tween urinary lithium and all fetalmeasurementswere generally inverse,
although not statistically signiﬁcant. Arsenic in urine was not statistically
signiﬁcant in any of the models.
In the fully adjusted cross-sectional linear regressionmodels (Table 2),
both blood and urine lithium concentrations were inversely associated
with all fetal measurements in the second trimester (N = 81; p values
generally b0.1), but not in the third trimester. In general, the full
adjustment of the 2nd trimester models markedly strengthened the
associations, compared to the model adjusted for gestational age only
(data not shown). The estimates based on blood lithium (per 25 μg/L)
corresponded to about one eighth of a standard deviation (SD) for BPD,
OFD, HC, AC and femur length.3.2. Associations between lithium exposure and birth measurements
In the linear regression models assessing birth outcomes in relation
to maternal lithium exposure (n= 174), adjusted for gestational age in
weeks and as quadratic term (Model 1), blood and urine lithium
(women's average blood and urine lithium concentrations during
pregnancy) were inversely associated (non-signiﬁcantly) with birth
weight and length (Table 3). Further adjusting (Model 2) strengthened
the inverse associations, which became statistically signiﬁcant for blood
lithium and birth length. Every 25 μg/L increase in blood lithium con-
centration was associated with a decrease of 0.53 cm (95%CI −1.0;
−0.052) in birth length. Similarly, newborns in the highest tertile of
lithium exposure (mean blood lithium 47 μg/L) were 0.81 cm shorter
compared with those in the lowest tertile (b18 μg/L, Table 3). In sensi-
tivity analyses, we excluded the individual with the highest blood lithi-
um levels (145 μg/L; leaving the next highest concentration at 109 μg/L)
and the two women with preeclampsia, which didn't change the esti-
mate for birth length (β−0.55, 95%CI−1.1;−0.0065, p = 0.047).4. Discussion
This population-based cohort study indicates, for the ﬁrst time, that
exposure to elevated drinking water lithium during pregnancy may ad-
versely affect fetal development. Both blood and urine lithium showed
consistent inverse associations with all fetal measurements (head,
femur, and abdomen) in the second trimester, indicating effects of lith-
ium in early gestation. Indeed, a younger and less developed fetus may
be particularly sensitive to the stress of lithium, as shown for other in-
sults (Barouki et al., 2012). At birth, infant length showed the strongest
Table 2
Linear regression models of fetal size measurements during the second (n = 81) and third trimesters (n = 98) of pregnancy in relation to maternal blood and urinary lithium
concentrations.
Fetal measurements Whole blood lithiuma Urinary lithiuma
2nd trimester 3rd trimester 2nd trimester 3rd trimester
β (95%CI)b p β (95%CI)b p β (95%CI)b p β (95%CI)b p
Biparietal diameter (cm) Mean ± SD: 5.0 ± 1.2 Mean ± SD: 8.1 ± 0.59 Mean ± SD: 5.0 ± 1.2 Mean ± SD: 8.1 ± 0.59
All −0.14 (−0.29; 0.014) 0.073 0.067 (−0.024; 0.16) 0.15 −0.091 (−0.19; 0.00051) 0.063 0.00063 (−0.060; .072) 0.85
Tertile 1 Ref: 5.0 cm Ref: 8.1 cm Ref: 5.0 cm Ref: 8.1 cm
Tertile 2 0.033 (−0.14; 0.21) 0.71 −0.043 (−0.27; 0.18) 0.72 −0.11 (−0.29; 0.068) 0.22 −0.095 (−0.27; 0.082) 0.29
Tertile 3 −0.068 (−0.31; 0.17) 0.57 −0.054 (−0.28; 0.18) 0.64 −0.18 (−0.40; 0.041) 0.11 −0.059 (−0.26; 0.14) 0.56
Occipitofrontal diameter (cm) Mean ± SD: 6.1 ± 1.4 Mean ± SD: 10 ± 0.76 Mean ± SD: 6.1 ± 1.4 Mean ± SD: 10 ± 0.76
All −0.19 (−0.40; 0.018) 0.073 0.012 (−0.15; 0.17) 0.88 −0.080 (−0.21; 0.052) 0.23 −0.056 (−0.17; 0.059) 0.33
Tertile 1 Ref: 6.1 cm Ref: 10.0 cm Ref: 6.1 cm Ref: 10.0 cm
Tertile 2 0.026 (−0.21; 0.26) 0.83 0.095 (−0.31; 0.50) 0.64 −0.11 (−0.35; 0.13) 0.36 −0.091 (−0.40; 0.22) 0.56
Tertile 3 −0.18 (−0.50; 0.15) 0.28 −0.043 (−0.44; 0.36) 0.83 −0.23 (−0.52; 0.064) 0.12 −0.14 (−0.49; 0.21) 0.42
Head circumference (cm) Mean ± SD: 19 ± 4.3 Mean ± SD: 30 ± 2.2 Mean ± SD: 19 ± 4.3 Mean ± SD: 30 ± 2.2
All −0.52 (−1.2; 0.13) 0.12 0.16 (−0.21; 0.53) 0.40 −0.32 (−0.72; 0.079) 0.11 −0.093 (−0.36; 0.17) 0.49
Tertile 1 Ref: 19 cm Ref: 30 cm Ref: 19 cm Ref: 30 cm
Tertile 2 0.29 (−0.42; 1.0) 0.41 0.13 (−0.81; 1.1) 0.79 −0.43 (−1.2; 0.30) 0.25 −0.59 (−1.3; 0.15) 0.12
Tertile 3 −0.40 (−1.4; 0.59) 0.42 −0.12 (−1.0; 0.80) 0.79 −0.83 (−1.7; 0.079) 0.073 −0.35 (−1.2; 0.47) 0.40
Abdominal circumference (cm) Mean ± SD: 17 ± 3.9 Mean ± SD: 29 ± 2.8 Mean ± SD: 17 ± 3.9 Mean ± SD: 29 ± 2.8
All −0.48 (−1.1; 0.089) 0.097 0.35 (−0.18; 0.90) 0.19 −0.24 (−0.60; 0.12) 0.19 0.055 (−0.33; 0.44) 0.78
Tertile 1 Ref: 17 cm Ref: 29 cm Ref: 17 cm Ref: 29 cm
Tertile 2 0.065 (−0.61; 0.74) 0.85 0.57 (−0.78; 1.9) 0.40 −0.52 (−1.2; 0.16) 0.13 −0.93 (−2.0; 0.10) 0.077
Tertile 3 −0.32 (−1.2; 0.55) 0.47 0.33 (−1.0; 1.7) 0.63 −0.65 (−1.5; 0.17) 0.12 −0.55 (−1.7; 0.61) 0.35
Femur length (cm) Mean ± SD: 3.5 ± 0.96 Mean ± SD: 6.3 ± 0.61 Mean ± SD: 3.5 ± 0.96 Mean ± SD: 6.3 ± 0.61
All −0.11 (−0.25; 0.024) 0.10 0.056 (−0.053; 0.17) 0.31 −0.074 (−0.16; 0.013) 0.093 −0.022 (−0.057; 0.10) 0.58
Tertile 1 Ref: 3.5 cm Ref: 6.3 cm Ref: 3.5 cm Ref: 6.3 cm
Tertile 2 −0.061 (−0.22; 0.096) 0.44 −0.018 (−0.30; 0.26) 0.90 −0.12 (−0.28; 0.039) 0.14 −0.052 (−0.27; 0.16) 0.63
Tertile 3 −0.13 (−0.35; 0.079) 0.22 −0.035 (−0.31; 0.24) 0.80 −0.23 (−0.43;−0.042) 0.018 −0.0071 (−0.25; 0.23) 0.95
Fetal weight (g) Mean ± SD: 497 ± 281 Mean + SD: 2107 ± 555 Mean ± SD: 497 ± 281 Mean + SD: 2107 ± 555
All −41 (−83; 1.5) 0.058 74 (−18; 167) 0.11 −24 (−54; 5.0) 0.10 −9.2 (−58; 77) 0.79
Tertile 1 Ref: 497 g Ref: 2107 g Ref: 497 g Ref: 2107 g
Tertile 2 5.6 (−45; 56) 0.83 48 (−191; 287) 0.69 −32 (−89; 25) 0.26 −169 (−348; 9.8) 0.064
Tertile 3 −14 (−79; 51) 0.67 −1.7 (−238; 234) 0.99 −42 (−110; 27) 0.23 −101 (−301; 100) 0.32
a Coefﬁcients are expressed as change per 25 μg/L for whole blood lithium and as change per 1000 μg/L for urinary lithium.
b Adjusted for: Gestational age (weeks) and gestational age (weeks) quadratic term, parity (number of pregnancies), family monthly income (≤500, N500 & b3000, N3000 (tertiles)
Argentinean pesos),maternal height (cm), infant sex (boys, girls), urinary arsenic (sumof arsenicmetabolites in urine, μg/L), whole blood cesium(μg/L) and serumboron (b80,≥80 μg/L).
52 F. Harari et al. / Environment International 77 (2015) 48–54inverse association with lithium. An increase in blood lithium concen-
trations of 100 μg/L (total range 1.9–145 μg/L), corresponding to about
140 μg/L in plasma,was associatedwith 2 cm shorter newborns (almost
one SD), similar to the ﬁndings for fetal femur length in the 2nd trimes-
ter. To note, serum concentrations during lithium therapy are usually
much higher, i.e. 3.5–10 mg/L (Grandjean and Aubry, 2009b). OurTable 3
Linear regression models of maternal exposure to lithium (whole blood and urinary lithium) i
Birth measurements Whole blood lithium
Model 1b Model 2c
β (95%CI) p β (95%CI)
Weight (g)
Alla −32 (−110; 48) 0.43 −35 (−126; 55)
Tertile 1 Ref: 3025 g Ref: 3025 g
Tertile 2 −56 (−198; 87) 0.44 −72 (−233; 89)
Tertile 3 −59 (−203; 85) 0.42 −54 (−225; 117)
Length (cm)
Alla −0.28 (−0.70; 0.13) 0.18 −0.53 (−1.0;−0.052)
Tertile 1 Ref: 47.6 cm Ref: 47.6 cm
Tertile 2 0.080 (−0.68; 0.84) 0.84 −0.40 (−1.3; 0.47)
Tertile 3 −0.39 (−1.1; 0.38) 0.32 −0.81 (−1.7; 0.12)
Head circumference (cm)
Alla 0.075 (−0.25; 0.4) 0.65 0.046 (−0.35; 0.44)
Tertile 1 Ref: 33.5 cm Ref: 33.5 cm
Tertile 2 0.36 (−0.25; 0.96) 0.24 0.33 (−0.38; 1.0)
Tertile 3 0.16 (−0.44; 0.77) 0.60 0.17 (−0.57; 0.92)
a Coefﬁcients are expressed as change per 25 μg/L for whole blood lithium and as change pe
b Adjusted for: Gestational age (weeks) and gestational age (weeks) quadratic term.
c Adjusted also for: parity (number of pregnancies), family monthly income (≤500, N500 &
urinary arsenic (sum of arsenic metabolites in urine, μg/L) and whole blood cesium (μg/L), serstatistical models were robust and the associations became generally
stronger after adjustments for potential confounders such as parity,
family income, maternal height or fetal sex, as well as other concurrent
exposures to arsenic, cesium or boron.
Unexpectedly, the associations with fetal size observed in the 2nd
trimester disappeared in the longitudinal analyses, which should haven relation to size at birth (n = 174).
Urinary lithium
Model 1b Model 2c
p β (95%CI) p β (95%CI) p
0.44 −3.6 (−65; 58) 0.91 −16 (−89; 58) 0.68
Ref: 3008 g Ref: 3008 g
0.38 −22 (−165; 122) 0.77 −35 (−199; 130) 0.68
0.53 −22 (−167; 122) 0.76 −56 (−228; 116) 0.52
0.030 −0.00066 (−0.32; 0.33) 0.99 −0.12 (−0.52; 0.28) 0.55
Ref: 47.4 cm Ref: 47.4 cm
0.37 0.42 (−0.34; 1.2) 0.28 0.16 (−0.89; 0.89) 1.00
0.086 0.26 (−0.52; 1.0) 0.51 −0.58 (−0.94; 0.93) 0.99
0.82 −0.059 (−0.32; 0.20) 0.66 −0.14 (−0.48; 0.19) 0.40
Ref: 33.8 cm Ref: 33.8 cm
0.36 0.17 (−0.44; 0.77) 0.58 −0.010 (−0.74; 0.72) 0.98
0.65 −0.21 (−0.82; 0.40) 0.50 −0.45 (−1.2; 0.32) 0.25
r 1000 μg/L for urinary lithium.
b3000, N3000 (tertiles) Argentinean pesos), maternal height (cm), infant sex (boys, girls),
um boron (b80, ≥80 μg/L).
53F. Harari et al. / Environment International 77 (2015) 48–54provided more power with about twice as many women. Possibly, the
well-documented uncertainties in fetal ultrasound measurements in
late pregnancy at which time also the inter-individual variations in fetal
growth increases (Geirsson, 1991), noted also in the present study (see
Supplemental material, Fig. S2), overshadowed the associations. Also,
the exposure measures might have been less representative in late
gestation. Lithium concentrations in urine increased with increasing
gestational age due to the physiologically change in glomerular ﬁltration
rate and thereby higher lithium clearance (30–50%) in late pregnancy
(Grandjean andAubry, 2009a). Hence, osmolality also decreasedwith ad-
vancing gestation (i.e. about 5.5 mOsm/Kg per gestational week; mean
osmolality in 1st trimester: 748mOsm/Kg) and the adjustment to the av-
erage osmolality in all urine samples may have contributed to higher ad-
justed urine lithium concentrations in late gestation. Less obvious to
explain is the increase in blood lithium concentrations in late gestation.
We speculate that it is related to the previously demonstrated increase
in the sodium–lithium counter-transport activity in erythrocytes near
term (Worley et al., 1982), possibly also an increase in lithium transport
in the small intestine (Diamond et al., 1983).
Our results ﬁnd some support in the literature, although the epidemi-
ological data on associations between maternal lithium medication and
pregnancy outcome are inconsistent. Two studies showed that lithium
therapy during pregnancy was associated with a lower birth weight
(Diav-Citrin et al., 2014; Kallen and Tandberg, 1983), while one found
an association with newborns large for gestational age (Jacobson et al.,
1992). None of these studies used fetal measurements by ultrasound or
lithium concentrations as exposure biomarker, and they focused on
birth weight only, not length or head circumference. An experimental
study onmice found no difference in pup birthweight of dams given lith-
ium in drinking water (347 mg/L) during pregnancy, compared to unex-
posed controls (Mroczka et al., 1983). However, the lithium-exposed
group showed statistically signiﬁcant impaired postnatal growth and de-
velopment. Another experimental study foundadecrease in organweight
in mouse pups of dams exposed to about 7 mg/L drinking water lithium
ad libitum (Messiha, 1993). Both experimental studies reported that the
developmental toxicity of lithium occurred particularly in the female
pups. We were not able to evaluate sex-differences in the effects of lithi-
um due to lack of power in the analyses.
The main ﬁndings of this study have also some support in the indi-
cated mechanisms of lithium toxicity. Lithium, from both therapy and
drinking water, crosses freely the placenta (Harari et al., 2012;
Newport et al., 2005) and is known to impair the thyroid hormones
(Broberg et al., 2011; Grandjean and Aubry, 2009c). Like most of the
hormones, the thyroid hormones play a critical role in fetal growth
and development (Forhead and Fowden, 2014). Other potential mecha-
nisms of lithium toxicity include direct or indirect impairment of para-
thyroid hormone and vitamin D (McKnight et al., 2012; Rosenblatt
et al., 1989), as well as increased cortisol levels (Bschor et al., 2002;
Sugawara et al., 1988). Further studies are warranted to understand
the mechanisms involved in the lithium-related impairment of fetal
development.
The potential long-term consequences of the observed associations
with fetal size remain to be elucidated. Low birth size has been shown
to be associated with impaired cognitive function (Broekman et al.,
2009; Kormos et al., 2014). Particularly, stunting during the ﬁrst stages
of life has been associated with e.g., insulin resistance and impaired
cognitive functions later in life, as well as with low birth weight in the
subsequent generation (Bennett et al., 2002; Dewey and Begum, 2011;
Grantham-McGregor et al., 2007).
The strengths of our study include the population-based designwith
high participation rate and large variation in lithium exposure. Also, the
studied womenwere nonsmokers with no alcohol consumption, which
reduced potential confounding. We put much effort in following
all women, even in themost distant villages, andwe established collab-
oration with the main hospital in Salta to collect samples and measure-
ments for the babies born there. We were able to adjust for potentialconfounders, such as exposure to boron, cesium and arsenic. However,
maternal mental health, known to inﬂuence fetal growth (Grigoriadis
et al., 2013; Huybrechts et al., 2014), was notmeasured. Information re-
gardingmedication (including lithium and other psychotropic drugs) as
well as any previous or current diseaseswas obtained through the inter-
views. Although no one reported either medication or diagnoses we
cannot rule out the possibility of underreporting or recall bias.
The main limitation of the study is the lack of ultrasound measure-
ments for all women.Missedmeasurementsweremainly due to limited
accessibility to the villages during the rain period (January–March),
which made it impossible for us to reach some of the areas, especially
Tolar Grande with known low lithium exposure (Concha et al., 2010).
We didn't have themeans to recruit a larger cohort in this ﬁrst invento-
ry study on environmental lithium exposure and early life effects, but
further and larger cohort studies are indeed warranted. To note, we
were not able to use serum lithium measurements as we found that
the serum tubes for analysis of trace elements, including lithium
(Vacuette®, Z Trace Elements Serum Clot Activator; Greiner bio-one,
Kremsmünster, Austria), contained appreciable amounts of lithium
(37 μg/L), invalidating our measurements (Lu et al., 2014). In a subsam-
ple we additionally measured concentrations in the plasma and found a
correlation (rs) of 0.99 with whole blood concentrations (N= 20; ratio
plasma/whole blood = 1.37). Thus, we considered blood lithium to re-
ﬂect the exposure equally well as plasma lithium. Importantly, the low
atmospheric oxygen concentration at high altitudes causes particular
stress on pregnancy and decreases the fertility rate. However, these ef-
fects are less common among indigenous people than thosewith Cauca-
sian inﬂuence (Kametas et al., 2004; Soria et al., 2013; Vitzthum, 2013),
and women in our study were mostly indigenous.
5. Conclusions
In conclusion, this study provides some indication that elevated
environmental lithium exposure during pregnancy might be inversely
associated with fetal size. Further studies are, however, necessary to
conﬁrm these ﬁndings and to understand the mechanisms involved.
Such studies should also be performed on pregnant women in lithium
therapy. The ﬁndings, if conﬁrmed, have obvious public health rele-
vance, but in any case there is a need for more measures of lithium in
drinking water. It should be noted that the brands of bottled water
with elevated lithium concentrations, similar to the highest in the
present study, increase steadily.
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